日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

巨噬细胞 Syk-PI3Kγ 抑制抗肿瘤免疫:新型双重 Syk-PI3K 抑制剂 SRX3207 可缓解肿瘤免疫抑制

Joshi, Shweta; Liu, Kevin X; Zulcic, Muamera; Singh, Alok R; Skola, Dylan; Glass, Christopher K; Sanders, P Dominick; Sharabi, Andrew B; Pham, Timothy V; Tamayo, Pablo; Shiang, Daniel; Dinh, Huy Q; Hedrick, Catherine C; Morales, Guillermo A; Garlich, Joseph R; Durden, Donald L

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

SF2523:双重PI3K/BRD4抑制剂阻断肿瘤免疫抑制并促进癌症适应性免疫反应

Joshi, Shweta; Singh, Alok R; Liu, Kevin X; Pham, Timothy V; Zulcic, Muamera; Skola, Dylan; Chun, Hyun Bae; Glass, Christopher K; Morales, Guillermo A; Garlich, Joseph R; Durden, Donald L

Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model

新型PI3激酶抑制剂SF1126在(12)V-Ha-Ras转基因小鼠胶质瘤模型中的抗肿瘤作用

Singh, Alok R; Joshi, Shweta; George, Elizabeth; Durden, Donald L

PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment

PTEN 和 PI-3 激酶抑制剂控制 CD19+ B 细胞群中的 LPS 信号传导和淋巴增殖反应。

Singh, Alok R; Peirce, Susan K; Joshi, Shweta; Durden, Donald L

PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression

PTEN状态介导2ME2在临床前胶质母细胞瘤模型中的抗肿瘤疗效:HIF1α抑制的作用

Muh, Carrie R; Joshi, Shweta; Singh, Alok R; Kesari, Santosh; Durden, Donald L; Makale, Milan T

Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo.

Rac2 在体内控制肿瘤生长、转移和 M1-M2 巨噬细胞分化

Joshi Shweta, Singh Alok R, Zulcic Muamera, Bao Lei, Messer Karen, Ideker Trey, Dutkowski Janusz, Durden Donald L